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Abstract
High circulating glucose has been associated with increased risk of breast cancer. There may also
be a link between serum glucose and prognosis in women treated for breast cancer. We assessed
the effect of peridiagnostic fasting blood glucose and body mass index (BMI) on long-term breast
cancer prognosis.
We retrospectively investigated 1261 women diagnosed and treated for stage I-III breast cancer at
the National Cancer Institute, Milan, in 1996, 1999, and 2000. Data on blood tests and follow-up
were obtained by linking electronic archives, with follow-up to end of 2009. Multivariate Cox
modelling estimated hazard ratios (HR) with 95% confidence intervals (CI) for distant metastasis,
recurrence and death (all causes) in relation to categorized peridiagnostic fasting blood glucose
and BMI. Mediation analysis investigated whether blood glucose mediated the BMI-breast cancer
prognosis association.
The risks of distant metastasis were significantly higher for all other quintiles compared to the
lowest glucose quintile (reference <87 mg/dL) (respective HRs: 1.99 95%CI 1.23-3.24, 1.85
95%CI 1.14-3.0, 1.73 95%CI 1.07-2.8, and 1.91 95%CI 1.15-3.17). The risk of recurrence was
significantly higher for all other glucose quintiles compared to the first. The risk of death was
significantly higher than reference in the second, fourth and fifth quintiles. Women with BMI ≥25
kg/m2 had significantly greater risks of recurrence and distant metastasis than those with BMI <25
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kg/m2, irrespective of blood glucose. The increased risks remained invariant over a median
follow-up of 9.5 years. Mediation analysis indicated that glucose and BMI had independent effects
on breast cancer prognosis.
Peridiagnostic high fasting glucose and obesity predict worsened short- and long-term outcomes in
breast cancer patients. Maintaining healthy blood glucose levels and normal weight may improve
prognosis.
Keywords
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Introduction
Breast cancer is the commonest cancer in women. A role of high circulating glucose in
carcinogenesis was first suggested by Warburg in the 1920s [1]. In 1962 it was reported that
two psychotic patients given insulin (with induction of hypoglycaemic coma) experienced
complete remission of metastatic breast cancer [2]. In 1977 Carroll reported an ecological
correlation between pro-capita sugar intake and breast cancer mortality [3]. In 2002, the
prospective ORDET study found that high fasting glucose was a risk factor for breast
cancer, further supported by a second ORDET study with longer follow-up [4,5].
By contrast Holmes et al. [6] found no association between glycaemic index or glycaemic
load, and breast cancer risk. A study on the Swedish National Diabetes Register cohort also
found no relation between diabetes and cancer [7].
The original observation of Warburg, that high glucose favours the selection of malignant
cell clones resistant to hypoxia, in which energy is produced mainly by glycolysis, is one
biological mechanism linking cancer development with high circulating glucose [8,9].
Enhanced glycolysis and glucose uptake characterizes most tumour cells [1]. Glucose
metabolism may also promote malignant change through the generation of free radicals that
damage both DNA and the enzymes involved in DNA repair and processing [10,11]. It has
also been found that levels of glucose transporters are elevated in most human cancers,
including breast cancer [12,13].
As regards breast cancer prognosis, evidence of a link to circulating glucose levels is more
limited. A study on cultured breast cancer cells found reduced chemotherapy-induced cell
death in cells subjected to high glucose concentrations, suggesting that hyperglycaemia
confers resistance to chemotherapy [14]. A dietary intervention study in breast cancer
patients found that the risk of recurrence was significantly higher in patients with metabolic
syndrome – one of whose main characteristics is elevated blood glucose [15].The HEAL
cohort study also provided some indication that dietary glycaemic load might be related to
breast cancer prognosis [16], while an observational study on 46 cancer patients, eight with
breast cancer, found significantly lower average blood glucose in patients in remission [17].
Finally, a recent cohort study on non-diabetic breast cancer patients found an association
between blood glucose and distant metastasis but only for the first five years after diagnosis
[18].
The aim of the present study was to investigate the relationship between long-term breast
cancer prognosis and fasting glucose levels by retrospectively examining two large
consecutive series of breast cancer patients. Furthermore, since high blood glucose is often
associated with overweight, we also investigated whether glucose and body mass index
(BMI) had independent or related effects on prognosis, and whether blood glucose mediates
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the association between BMI and prognosis. We evaluated the effects of these variables on
any breast cancer recurrence, distant metastasis, and death for any cause.
Methods
Patients
We retrospectively examined two consecutive series of breast cancer (BC) patients treated at
the National Cancer Institute of Milan (NCIM) in 1996 and 1999-2000, adhering to the
following criteria: resident in the Region of Lombardy at moment of diagnosis, no previous
cancer diagnosis (except non-melanoma skin cancer), fasting blood glucose determined
peridiagnostically (and available), and stage I-III breast cancer (T1-T3, N0-N1, M0). We
conducted a pilot investigation of cases from 1999 to 2000 and subsequently added 1996
cases to increase cohort size and lengthen median follow-up.
Cases were initially identified automatically from the prospectively maintained electronic
database of NCIM case records (Step 1a, Figure 1). We next used the Epilink software to
perform statistically-based linkage of NCIM cases to hospital discharge files for the entire
Region of Lombardy [19]. This process also involved linkage to Region of Lombardy Social
Security files in order to verify Region of Lombardy residency. The outcome of this
procedure was that incident cases (Step 2, Figure 1) were separated from prevalent cases
which were eliminated.
In a separate procedure (Step 1b, Figure 1) we applied Epilink to cases archived in the
NCIM analytical laboratory database, selecting female patients with fasting glucose
determinations.
To identify BC cases (incident at NCIM in the study years) that also had peridiagnostic
fasting glucose we manually checked the few records (1%) flagged by Epilink in Steps 1a
and 1b as having uncertain linkage, and linked cases from Step 1b with those from Step 2.
The next step (Step 3, Figure 1) was hand-searching the clinical records of identified cases.
This served as an additional check that case details were correct, and provided the following
additional information: BMI (kg/m2), disease stage (TNM), menopausal status at diagnosis,
and tumour estrogen and progesterone receptor data. A series of algorithms included in the
Open Registry software [20] was then applied to ascertain whether any adverse breast cancer
events for these cases had been registered in the hospital discharge database of the Region of
Lombardy from 1996 to 2009. Cases with an adverse event were then hand-searched in
clinical records (Step 4, Figure 1) to confirm the event and obtain details (locoregional
recurrence, distant metastasis, death). Finally (Step 5, Figure 1), the vital status of all cases
was checked on Social Security files up to 31/12/2009 (end of follow-up). Thirty-one (2.5%)
women were identified as having moved out of the Region of Lombardy before the close of
follow-up and were considered lost to follow-up at the date of moving.
Statistical methods
Associations between glucose and other patient variables were analysed by chi-square test,
with glucose categorized into quintiles, and age, menopausal status, tumour stage, BMI, and
estrogen and progesterone receptor status, categorized as in Table 1. Spearman rank
correlation coefficients were determined to examine correlations between selected variables.
The study had three end-points: any breast cancer recurrence, distant metastasis, and all-
cause mortality. Some women contributed to all three endpoints. The Kaplan-Meier method
was used to visualize the effects of variables on endpoints. Cox proportional hazard
modelling was used to estimate hazard ratios (HRs) with 95% confidence intervals (CI) for
any recurrence, distant metastasis, and all-cause death by quintiles of fasting blood glucose
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(lowest as reference), also by dichotomized BMI (<25 kg/m2 vs. ≥25 kg/m2, lower as
reference), adjusting by age (five-year classes), menopausal status (according to Table 1
categories), estrogen and progesterone receptor status (positive or negative) and tumour
stage. Postmenopausal status was defined as absence of menstruation for at least 12 months.
Time to an event or end of follow-up was calculated from date of diagnosis. The
proportional hazards assumption was tested by analysis of scaled Schoenfeld residuals, with
p values for each variable estimated. When the hazard for a variable was suspected to be
non-proportional over time, we performed additional analyses, substituting the conventional
Cox model β coefficient (for a given variable) with a time-dependent function β(t) obtained
by adding the smoothed scaled Schoenfeld residuals to the conventional β coefficient [21].
The results were evaluated as suggested by Grambsch et al. [19] and Bellera et al. [22].
When non-proportional hazards were found for covariates other than glucose and BMI, we
stratified the Cox models by these covariates.
We ran semi-adjusted models that included all covariates except glucose (when assessing
BMI) and BMI (when assessing glucose), and fully-adjusted models that included all
covariates (including glucose and BMI). The methodology of MacKinnon et al. [23] was
employed to test whether blood glucose mediates the causal relationship between BMI and
breast cancer prognosis. To be considered a mediator of this relationship, blood glucose: (a)
must be correlate with BMI; (b) must remain associated with prognosis after adjusting for
BMI; (c) must partially or totally explain the effect of BMI on prognosis.
(a) was assessed by correlation analysis and (b) by Cox proportional hazards analysis. To
ascertain (c) we calculated β for BMI in the semi-adjusted model without blood glucose,
then ran the fully-adjusted model adding blood glucose into the analysis and obtaining a new
coefficient (β’) for BMI. We then tested the β - β’ difference by the Freedman and Scatzkin
test [24]. The percentage attenuation of β following the introduction of blood glucose
introduction was calculated as ((β - β’) / β) * 100. The analyses were performed using the R
statistical package [25].
Results
Cohort
A total of 12,028 women in the NCIM hospital discharge database, years 1996, 1999 and
2000, had a diagnosis of breast cancer. By linkage with Social Security files 5509 of these
had a Region of Lombardy residence code. By linkage of these cases with Lombardy
hospital discharge files for years prior to the study period, 3651 women were excluded as
prevalent cases or as having a diagnosis of another cancer, and 1858 cases were identified as
incident breast cancers. In a separate process, records of blood glucose tests performed by
the NCIM analytical laboratory, in the years of the study, were linked with Social Security
files, from which 18,393 records were identified as belonging to female residents in the
Region of Lombardy. By linkage of these cases with the 1858 incident breast cancer cases,
1759 breast cancers cases with peridiagnostic glucose levels were identified, and 99 were
excluded. Hand-searching of the clinical records of these cases led to the exclusion of a
further 498 cases of prevalent (N=195), stage unknown (N=142), non-invasive (N=95), or
metastatic (N=66) breast cancer at diagnosis. We conducted the analysis on 1261 cases, fully
respecting the predefined study criteria.
The clinical characteristics of these cases are shown in Table 1. During a median follow-up
of 9.5 years (maximum 13.5 years), 107 locoregional recurrences, 293 distant metastases
and 317 deaths were identified (more than one event possible in any woman). Two thirds
(65.2%) of the women were postmenopausal. Mean age was 57 years. Mean fasting glucose
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was 100.6 mg/dL (range 68-401). Women with high glucose were more likely to be older,
more often menopausal, have higher BMI, and more advanced disease stage at diagnosis.
Disease progression and fasting glucose—Preliminary analyses identified non-
proportional hazards in relation to estrogen receptor status, progesterone receptor status,
disease stage, and age, so the final models were stratified for these variables.
In the semi-adjusted model (without BMI), HRs for distant metastasis were significantly
above reference (lowest quintile) for women in the other four quintiles of the glucose
distribution (Table 2). In the fully-adjusted model (with BMI), HRs were slightly lower but
always significantly greater than reference.
Risk of any breast cancer recurrence was also significantly above reference for women in
the other four glucose quintiles in the semi-adjusted model, but were attenuated in the fully-
adjusted model, when they were no longer significant for the third and fourth quintiles. The
risk of all-cause death was significantly above reference for women in the second, fourth
and fifth glucose quintiles in the fully-adjusted model (Table 2).
High glucose was associated with increased risk of distant metastasis in both categories of
BMI. For <25 kg/m2 BMI women, HRs by increasing quintiles were 2.32 (95%CI
0.99-4.12), 2.33 (95%CI 0.89-3.97), 2.23 (95%CI 1.07-4.64), and 1.73 (95%CI 0.47-3.39).
For those with BMI ≥25 kg/m2, the corresponding HRs were 1.22 (95%CI 0.49-3.01), 1.56
(95%CI 0.69-3.55), 1.13 (95%CI 0.52-2.47) and 1.74 (0.78-3.86) (fully adjusted models,
data not shown in Tables). Analysis (fully adjusted model) indicated no interaction between
fasting glucose and BMI.
High glucose was associated with increased risk of distant metastasis in both categories of
menopausal status. For premenopausal women, HRs for increasing glucose quintiles were
2.49 (95%CI 1.27-4.90), 2.05 (95%CI 1.0-4.20), 2.30 (95%CI 1.07-4.97), and 0.64 (95%CI
0.14-2.93); for postmenopausal women the corresponding HRs were 1.43 (95%CI
0.68-2.99), 1.47 (95%CI 0.73-2.91); 1.37 (95%CI 0.70-2.62), and 1.89 (95%CI 0.99-3.62)
(fully adjusted models, data not shown in Tables). The low HR and wide confidence limits
for the upper quintile of premenopausal women is probably due to the fact that it contained
few women (N=32). Analysis (fully adjusted model) indicated no interaction between
fasting glucose and menopausal status.
To further probe the relationship between fasting glucose and prognosis we repeated the
analyses with the covariate BMI categorized as recommended by the WHO (<18.5;
≥18.5<25; ≥25<30; ≥30 kg/m2) and also considering BMI as a continuous variable. The
results (not shown in Tables) were closely similar to those shown in Tables 2 and 3. For
example the HR for distant metastasis in the highest glucose quintile was 1.72 compared to
reference, while with BMI as continuous variable the corresponding HR was 1.74. (c.f. HR
1.91 in Table 2).
Disease progression and BMI—Compared to reference (<25 kg/m2) women with BMI
≥25 kg/m2 had significantly greater risks of any recurrence and distant metastasis, but not
death (Table 3). In the semi-adjusted model (excluding glucose) the HR for distant
metastasis was 1.57 (95%CI 1.17-2.10) in the higher BMI category, and remained
significant in the fully adjusted model. Risk of any recurrence was also significantly
influenced by BMI both in the semi- and fully-adjusted models, but BMI had only a minor
effect on all-cause mortality (Table 3).
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Prognostic effects of high glucose and high BMI over time—Analyses of scaled
Schoenfeld residuals showed that the proportional hazard assumption held for glucose over
time. Specifically, for distant metastasis as outcome, p values for increasing glucose
quintiles compared to the lowest were 0.11, 0.47, 0.42 and 0.06, indicating that the null
hypothesis of no variation of hazard with time could not be rejected, and suggesting that the
prognostic effect of glucose remained constant over the entire follow-up period. A similar
result (P=0.48) was obtained for the upper BMI category compared to reference. Hazard
proportionality was also investigated for all recurrences and mortality, and found to hold for
glucose and BMI (data not shown), implying that the prognostic effect of glucose and BMI
on these endpoints remained constant over the entire follow-up.
Mediation analysis of relationship between fasting glucose and BMI—Fasting
glucose and BMI correlated with each other (Spearman’s r=0.28, p=0.002) hence satisfying
the first MacKinnon et al. [23] criterion. Fasting glucose also remained associated with
prognosis after the introduction of the BMI into the statistical model as shown above
(criterion b). We next applied MacKinnon [23] criterion (c) to determine whether blood
glucose partially or totally explained the effect of BMI on prognosis. With distant metastasis
as outcome the attenuation percentage was 13%, and Freedman-Schatzkin test P value was
0.46, so the null hypothesis that blood glucose did not mediate the effect of BMI on distant
metastasis could not be rejected. With any recurrence as outcome, attenuation percentage
was 13.8%, Freedman-Schatzkin test P value 0.53, so again the null hypothesis that that
blood glucose did not mediate the effect of BMI any recurrence could not be rejected.
Finally BMI was not significantly associated with death either before or after the
introduction blood glucose into the statistical model, so again the null hypothesis (that blood
glucose did not mediate the effect of BMI on death recurrence) was not rejected. We also
did mediation analysis with BMI categorized into four levels, and as a continuous variable:
in all cases results indicated that the null hypothesis of no mediation.
Discussion
The principal finding of this retrospective study on 1261 women with invasive breast cancer
is that risks of any recurrence and of distant metastasis were significantly higher for those
with fasting blood glucose in the four high quintiles of the distribution, compared to those in
the lowest quintile (<87 mg/dL). Risk of death for any cause showed a similarly significant
pattern. These risks were attenuated, but still usually significant, in the fully-adjusted model
that included BMI (Table 2); while models run for high and low BMI separately estimated
similarly increased risks for all quintiles of glucose above reference, although these were not
significant in most cases, probably due to the considerably lower numbers of cases in each
category.
We also found that BMI was related to breast cancer prognosis: the risks of breast cancer
recurrence and distant metastasis were significantly higher in overweight plus obese women
(BMI ≥25 kg/m2) than normal weight plus underweight women (BMI <25 kg/m2). These
risks were slightly attenuated in the fully adjusted model (with glucose as covariate). BMI
was not significantly associated with all-cause death.
Importantly, our analysis also indicated that the worsened prognosis of women with high
glucose and high BMI remained constant over the entire follow-up.
The recent study of Goodwin et al. investigated insulin-related (including fasting glucose)
and obesity-related variables in 535 non-diabetic women treated for T1-3 N0-1 M0 breast
cancer [18]. They found that insulin-related variables (including glucose) were significantly
associated with distant metastasis only for the first five years of follow-up; by contrast our
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study suggests that the increased risk persists over the long term. In both studies the risks
associated with BMI remained constant over time. Unlike the present study, Goodwin et al.
found no significant association of fasting glucose with overall mortality.
The Diana-2 study investigated the relation of metabolic syndrome and its components to
breast cancer prognosis [15]. Metabolic syndrome at baseline was associated with an
adjusted HR for recurrence of 3.0 (95%CI 1.2-7.1) relative to no metabolic syndrome. High
blood glucose (component of metabolic syndrome) was also associated with increased HRs
for recurrence, but the association was not significant, probably in relation to the small
numbers of both patients (N=110) and adverse events (N=31).
The HEAL study investigated relations of dietary fibre, glycaemic index and glycaemic load
to adverse events in 688 breast cancer patients followed for 6.7 years [16]. There was some
indication that high glycaemic index was related to increased breast cancer mortality and
recurrences, but risk increases were not significant. Dietary glycaemic index and dietary
glycaemic load may not correlate closely with fasting blood glucose.
With regard to the influence of obesity on breast cancer prognosis, this has been investigated
by several studies [26-28]. Ewertz et al. [26] analysed 18,967 Danish women treated for
early breast cancer between 1977 and 2006. For the first five years after diagnosis there was
no association between BMI and distant metastasis, from five years on (at least 10 years of
follow-up) obesity (BMI ≥30 kg/m2) and overweight (BMI 25-29 kg/m2) were associated
with significantly greater risk of distant metastases after adjusting the models for disease
characteristics.
A retrospective analysis of 2,887 lymph node-positive breast cancer patients enrolled in the
BIG 02-98 study [27] also found that baseline obesity was associated with significantly
poorer outcomes. A meta-analysis of 43 studies, published in 2008, found an HR for breast
cancer-specific mortality of 1.33 (95%CI 1.19-1.50) in obese patients compared to non-
obese patients [28].
The findings of the present study on the prognostic effect of fasting glucose are, therefore,
consistent with the results of previous studies and are reinforced by plausible biological
mechanisms for effects of glucose on breast cancer [1-5, 8-9, 12-13].
Our study is the first to use statistical methods investigate whether fasting glucose levels
mediated the association between BMI and breast cancer prognosis. Our extensive analyses
indicated that fasting glucose did not mediate this relationship, indicating that glucose and
BMI have independent effects on BC prognosis.
A limitation of our study is that fasting glucose was only measured once. It would be useful
to assess blood glucose at several time points during follow-up in the expectation that
women with chronically high glucose would be at even greater risk of adverse events, and
that those who correct hyperglycaemia and overweight have lowered risks.
Other limitation are the lack of information on comorbidities and biological factors like
tumour proliferation rate and human epidermal growth factor receptor 2 overexpression,
both of which are known to influence breast cancer prognosis, and lack of information about
the use of diabetic medications to lower blood sugar levels medications.
It is noteworthy that 85% of our cohort had fasting serum glucose in the four highest
quintiles, or BMI ≥25 kg/m2, or both. Thus a large vast majority of the patients in our cohort
were at high risk of recurrence.
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Conclusions
At the very least our data indicate that studies are necessary to determine whether long-term
control of hyperglycaemia and reduction of obesity improves breast cancer outcomes.
Rapid and profound changes of in eating habits are occurring in many countries, particularly
those in South Asia, Africa, Latin America and China, that have been linked to increased
incidence of obesity and chronic diseases [29-32]. Thus in Brazil more sugar is consumed
than recommended by the WHO, and added sugars from processed foods and manufactured
beverages form an increasing proportion of sugar intake [33]. The World Health
Organization estimates that by 2015 over 2.3 billion people will be overweight, and that
deaths due to diabetes will have increased by more than 50% [34]. These projections suggest
we are likely to see in increase in the proportion of breast cancer patients with high blood
sugar levels, who will have, according to our findings, worsened prognosis for their disease
compared to earlier periods. These considerations provide additional reasons why
Governments should place food behaviour policy very high on their health agenda.
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Fig. 1.
Flow-chart illustrating how incident breast cancer cases with fasting glucose determined
peridiagnostically were identified and follow-up information obtained. Octagons show
processes; rectangles show outputs.
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